Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 1/20 | 0.38 |
| ▸ | PGK2 | P07205 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6044962 | 0.84 | PGK1 (0.35) | PGK1PGK2 | |
| SCHEMBL4544109 | 0.81 | PGK1 (0.41) | PGK1PGK2CYP1A2BRD4 | |
| SCHEMBL6044969 | 0.78 | PGK1 (0.60) | PGK1PGK2CYP1A2POLBMEN1 | |
| SCHEMBL6044952 | 0.65 | PGK1 (0.53) | PGK1PGK2 | |
| SCHEMBL17489025 | 0.65 | PGK1 (0.53) | PGK1PGK2CYP1A2MEN1KMT2A | |
| SCHEMBL4544102 | 0.64 | PGK1 (0.62) | PGK1PGK2CYP1A2POLBNPSR1 | |
| SCHEMBL5010543 | 0.64 | PGK1 (0.52) | PGK1PGK2MAPTPOLBNPSR1 | |
| SCHEMBL6044980 | 0.63 | PGK1 (0.38) | PGK1PGK2CYP1A2 | |
| SCHEMBL6044987 | 0.63 | PGK1 (0.38) | PGK1PGK2CYP1A2NR1I2 | |
| SCHEMBL915800 | 0.62 | TSHR (0.52) | POLBMEN1KMT2ANR1I2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060210479-A1 | Targeting chelants and chelates | DOW GLOBAL TECHNOLOGIES INC. (US) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060210479-A1 | Targeting chelants and chelates | CLTC, CALCOCO2, TFRC | PGK1 2785/4885PGK2 2466/4885CYP1A2 4844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.